Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
ACTG Announces Publication of Pivotal Hepatitis C Study in Clinical Infectious Diseases
Details : ACTG 5360 is a combination of sofosbuvir which is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, whereas velpatasvir is an inhibitor of the HCV NS5A protein, both required for viral replication. Currently being studied for chronic hepatitis C...
Brand Name : ACTG 5360
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Lead Product(s) : Sofosbuvir,Velpatasvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase IV
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sofosbuvir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Researchers Identify Multiple Molecules tat Shut Down SARS-Cov-2 Polymerase Reaction
Details : Researchers at Columbia Engineering and the University of Wisconsin-Madison have identified a library of molecules that shut down the SARS-CoV-2 polymerase reaction. Five of these molecules are already FDA-approved for use in the treatment of other viral...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2020
Lead Product(s) : Sofosbuvir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?